Is Fam-trastuzumab deruxtecan-nxki included in medical insurance?

Fam-trastuzumab deruxtecan-nxki (Fam-trastuzumab deruxtecan-nxki) is a HER-2-directed antibody linked to a topoisomerase inhibitor and is approved for certain types of metastatic, unresectable breast cancer, gastric cancer, and non-small cell lung cancer. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to conjugate the antibody and drug sets this product apart from other members of its class.

In the United States, trastuzumab is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received an anti-HER2-based regimen, either in the neoadjuvant or adjuvant setting, and who have experienced disease recurrence during or within six months of completing treatment. It is also indicated for the treatment of adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have previously received chemotherapy in the metastatic setting or who have experienced disease recurrence during or within six months of completing adjuvant chemotherapy. Trastuzumab is also indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have previously received a trastuzumab-based regimen.

Trastuzumab is a new type of injectable anti-cancer drug. The original drug has been launched in China, but it has not yet entered the scope of medical insurance. It is a strictly controlled drug. The domestic price is not yet clear, and its purchase method is difficult. The Hong Kong version of TrastuzumabSpecifications100mg may cost more than 10,000 yuan per box, and the Hong Kong original versionTrastuzumabOriginal drug specificationsThe price of 100mg per box may be around 15,000 yuan (the price may fluctuate due to exchange rate effects). The drug ingredients of the two are basically the same. There is currently no generic drug of Trastuzumab produced and launched. For more specific prices and drug information, please consult the medical consultant of the drug.